In an effort to battle against what members feel is an existential threat to their businesses, a group of 10 domestic biotech companies has launched the Midsized Biotech Alliance of America (MBAA) ...
Experts unpacked MFN drug pricing, expired ACA subsidies, and IRA fallout for community oncology in a recent webinar. The panelists were Lindsay Bealor Greenleaf, JD, MBA, head of market access policy ...
Democrats press 11 pharmas for 'any evidence' their Trump pricing deals deliver savings for Medicaid
Although major pharmaceutical companies have fallen in line with President Donald Trump’s “most favored nation” (MFN) drug pricing agenda, the specifics of their negotiated concessions and the actu | ...
Senators are probing which products fall under Medicaid-related deal provisions and whether any “MFN” prices are meaningfully lower than current Medicaid net prices after rebates.
The Trump administration reignited the U.S. drug pricing debate by signing a sweeping Executive Order on May 12, introducing a “Most Favored Nation” (MFN) pricing framework. This policy seeks to ...
Voluntary MFN commitments by 16 manufacturers reportedly cover ~70% of Medicare drug spending, potentially obviating GUARD/GLOBE finalization while avoiding predictable legal challenges. Lindsay ...
On July 31, the Trump administration called on drug manufacturers to lower prescription drug prices in the U.S. to "most favored nation" – or MFN – pricing, the lowest cost paid for the same ...
A proposed US most-favored nation (MFN) drug-pricing rule is adding a new source of uncertainty to healthcare dealmaking, prompting private equity investors to reassess exposure to pharma, ...
Most Favored Nation or "MFN" drug pricing is a policy through which prescription drug prices in the United States are aligned with the lowest prices paid for the same drugs in other developed nations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results